Cargando…

Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy

BACKGROUND: Good performance status (PS) is widely acknowledged to have a high prognostic ability, although the prognostic parameters of cancer patients with good PS are still uncertain. This study was conducted to establish and validate a point-based nomogram to assist with predicting prognosis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin, Yang, Bowen, Li, Zhi, Qu, Jinglei, Liu, Jing, Song, Na, Chen, Ying, Cheng, Yu, Zhang, Simeng, Wang, Zhongqing, Qu, Xiujuan, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186730/
https://www.ncbi.nlm.nih.gov/pubmed/32355755
http://dx.doi.org/10.21037/atm.2020.02.131
_version_ 1783527016006418432
author Wang, Jin
Yang, Bowen
Li, Zhi
Qu, Jinglei
Liu, Jing
Song, Na
Chen, Ying
Cheng, Yu
Zhang, Simeng
Wang, Zhongqing
Qu, Xiujuan
Liu, Yunpeng
author_facet Wang, Jin
Yang, Bowen
Li, Zhi
Qu, Jinglei
Liu, Jing
Song, Na
Chen, Ying
Cheng, Yu
Zhang, Simeng
Wang, Zhongqing
Qu, Xiujuan
Liu, Yunpeng
author_sort Wang, Jin
collection PubMed
description BACKGROUND: Good performance status (PS) is widely acknowledged to have a high prognostic ability, although the prognostic parameters of cancer patients with good PS are still uncertain. This study was conducted to establish and validate a point-based nomogram to assist with predicting prognosis in unresectable or metastatic gastric cancer (GC) patients who had good PS and underwent first-line chemotherapy. METHODS: At random, a total of 309 patients with GC were split into 2 cohorts: a training cohort (n=259) and an internal validation cohort (n=50). An independent external validation cohort comprising 147 patients was also recruited. Both univariate and multivariate Cox regression analyses were used to evaluate patients based on the overall survival (OS) to develop the nomogram, which was subsequently validated using the concordance index (c-index), calibration curve, and decision curve analysis (DCA). RESULTS: The nomogram contained 3 independent prognostic variables in the training cohort: the number of distant metastatic sites (P<0.001), carbohydrate antigen 199 (CA199) level (P=0.002), and fibrinogen (P=0.020). The nomogram predicted an OS with a c-index of 0.623 (95% CI, 0.58–0.67) in the training cohort. The internal validation showed that the nomogram had a c-index of 0.614 (95% CI, 0.51–0.72). For external validation, the c-index was 0.638 (95% CI, 0.58–0.70). CONCLUSIONS: A reliable point-based nomogram for predicting the prognosis of patients who had unresectable or metastatic GC and good PS who underwent first-line chemotherapy was developed and validated. KEYWORDS: Nomogram-based prediction; overall survival; unresectable gastric cancer; metastatic gastric cancer; good performance status; first-line chemotherapy
format Online
Article
Text
id pubmed-7186730
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71867302020-04-30 Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy Wang, Jin Yang, Bowen Li, Zhi Qu, Jinglei Liu, Jing Song, Na Chen, Ying Cheng, Yu Zhang, Simeng Wang, Zhongqing Qu, Xiujuan Liu, Yunpeng Ann Transl Med Original Article BACKGROUND: Good performance status (PS) is widely acknowledged to have a high prognostic ability, although the prognostic parameters of cancer patients with good PS are still uncertain. This study was conducted to establish and validate a point-based nomogram to assist with predicting prognosis in unresectable or metastatic gastric cancer (GC) patients who had good PS and underwent first-line chemotherapy. METHODS: At random, a total of 309 patients with GC were split into 2 cohorts: a training cohort (n=259) and an internal validation cohort (n=50). An independent external validation cohort comprising 147 patients was also recruited. Both univariate and multivariate Cox regression analyses were used to evaluate patients based on the overall survival (OS) to develop the nomogram, which was subsequently validated using the concordance index (c-index), calibration curve, and decision curve analysis (DCA). RESULTS: The nomogram contained 3 independent prognostic variables in the training cohort: the number of distant metastatic sites (P<0.001), carbohydrate antigen 199 (CA199) level (P=0.002), and fibrinogen (P=0.020). The nomogram predicted an OS with a c-index of 0.623 (95% CI, 0.58–0.67) in the training cohort. The internal validation showed that the nomogram had a c-index of 0.614 (95% CI, 0.51–0.72). For external validation, the c-index was 0.638 (95% CI, 0.58–0.70). CONCLUSIONS: A reliable point-based nomogram for predicting the prognosis of patients who had unresectable or metastatic GC and good PS who underwent first-line chemotherapy was developed and validated. KEYWORDS: Nomogram-based prediction; overall survival; unresectable gastric cancer; metastatic gastric cancer; good performance status; first-line chemotherapy AME Publishing Company 2020-03 /pmc/articles/PMC7186730/ /pubmed/32355755 http://dx.doi.org/10.21037/atm.2020.02.131 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Jin
Yang, Bowen
Li, Zhi
Qu, Jinglei
Liu, Jing
Song, Na
Chen, Ying
Cheng, Yu
Zhang, Simeng
Wang, Zhongqing
Qu, Xiujuan
Liu, Yunpeng
Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title_full Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title_fullStr Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title_full_unstemmed Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title_short Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
title_sort nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186730/
https://www.ncbi.nlm.nih.gov/pubmed/32355755
http://dx.doi.org/10.21037/atm.2020.02.131
work_keys_str_mv AT wangjin nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT yangbowen nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT lizhi nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT qujinglei nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT liujing nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT songna nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT chenying nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT chengyu nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT zhangsimeng nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT wangzhongqing nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT quxiujuan nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy
AT liuyunpeng nomogrambasedpredictionofsurvivalinunresectableormetastaticgastriccancerpatientswithgoodperformancestatuswhoreceivedfirstlinechemotherapy